Cancer-related fatigue: a review.

Maira Paschoin de Oliveira Campos, Benjamin Joseph Hassan, Rachel Riechelmann, Auro Del Giglio

Research output: Contribution to journalArticle

Abstract

Cancer-related fatigue is the most prevalent cancer symptom, reported in 50%-90% of patients and severely impacts quality of life and functional capacity. The condition remains underreported and often goes untreated. Guidelines suggest screening for fatigue at the initial visit, when the diagnosis of advanced disease is made, and at each chemotherapy session, as well as the identification of treatable contributing factors such as anemia, hypothyroidism, depression and sleep disorders. Brief assessment tools such as the Brief Fatigue Inventory or the Visual Analog Scale may be appropriate in the initial scoring of fatigue severity, but the initial approach to treatment usually requires a more comprehensive assessment, education, and the determination of an individualized treatment plan. Patients with moderate or severe fatigue may benefit from both pharmacological and non-pharmacological interventions, whereas mild fatigue that does not interfere with quality of life can be treated with non-pharmacological measures alone. Non-pharmacological measures that have shown to be promising include cognitive-behavioral interventions such as energy conservation and activity management (ECAM), exercise and perhaps sleep therapy. Many other modalities may be beneficial and can be used on an individual basis, but there is insufficient evidence to promote any single treatment. Pharmacological therapies that have shown to be promising include the psycho-stimulants methylphenidate and dexmethylphenidate, modafinil (in severely fatigued patients only), and erythropoietin-stimulating agents in patients with chemotherapy-associated anemia and hemoglobin levels < 10 g/dL. Recently, our group reported impressive results with the use of the dry extract of Guarana (Paullinia cupana), with no significant side effects and at low cost, for the treatment of physical and mental cancer-related fatigue.

Original languageEnglish
Pages (from-to)211-219
Number of pages9
JournalRevista da Associação Médica Brasileira (1992)
Volume57
Issue number2
StatePublished - Apr 1 2011

Fingerprint

Fatigue
Paullinia
Neoplasms
Anemia
Quality of Life
Pharmacology
Therapeutics
Drug Therapy
Methylphenidate
Proxy
Erythropoietin
Hypothyroidism
Visual Analog Scale
Health Care Costs
Sleep
Hemoglobins
Guidelines
Exercise
Depression
Education

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Campos, M. P. D. O., Hassan, B. J., Riechelmann, R., & Del Giglio, A. (2011). Cancer-related fatigue: a review. Revista da Associação Médica Brasileira (1992), 57(2), 211-219.

Cancer-related fatigue : a review. / Campos, Maira Paschoin de Oliveira; Hassan, Benjamin Joseph; Riechelmann, Rachel; Del Giglio, Auro.

In: Revista da Associação Médica Brasileira (1992), Vol. 57, No. 2, 01.04.2011, p. 211-219.

Research output: Contribution to journalArticle

Campos, MPDO, Hassan, BJ, Riechelmann, R & Del Giglio, A 2011, 'Cancer-related fatigue: a review.', Revista da Associação Médica Brasileira (1992), vol. 57, no. 2, pp. 211-219.
Campos MPDO, Hassan BJ, Riechelmann R, Del Giglio A. Cancer-related fatigue: a review. Revista da Associação Médica Brasileira (1992). 2011 Apr 1;57(2):211-219.
Campos, Maira Paschoin de Oliveira ; Hassan, Benjamin Joseph ; Riechelmann, Rachel ; Del Giglio, Auro. / Cancer-related fatigue : a review. In: Revista da Associação Médica Brasileira (1992). 2011 ; Vol. 57, No. 2. pp. 211-219.
@article{5172187de94840e49565f6073eff017e,
title = "Cancer-related fatigue: a review.",
abstract = "Cancer-related fatigue is the most prevalent cancer symptom, reported in 50{\%}-90{\%} of patients and severely impacts quality of life and functional capacity. The condition remains underreported and often goes untreated. Guidelines suggest screening for fatigue at the initial visit, when the diagnosis of advanced disease is made, and at each chemotherapy session, as well as the identification of treatable contributing factors such as anemia, hypothyroidism, depression and sleep disorders. Brief assessment tools such as the Brief Fatigue Inventory or the Visual Analog Scale may be appropriate in the initial scoring of fatigue severity, but the initial approach to treatment usually requires a more comprehensive assessment, education, and the determination of an individualized treatment plan. Patients with moderate or severe fatigue may benefit from both pharmacological and non-pharmacological interventions, whereas mild fatigue that does not interfere with quality of life can be treated with non-pharmacological measures alone. Non-pharmacological measures that have shown to be promising include cognitive-behavioral interventions such as energy conservation and activity management (ECAM), exercise and perhaps sleep therapy. Many other modalities may be beneficial and can be used on an individual basis, but there is insufficient evidence to promote any single treatment. Pharmacological therapies that have shown to be promising include the psycho-stimulants methylphenidate and dexmethylphenidate, modafinil (in severely fatigued patients only), and erythropoietin-stimulating agents in patients with chemotherapy-associated anemia and hemoglobin levels < 10 g/dL. Recently, our group reported impressive results with the use of the dry extract of Guarana (Paullinia cupana), with no significant side effects and at low cost, for the treatment of physical and mental cancer-related fatigue.",
author = "Campos, {Maira Paschoin de Oliveira} and Hassan, {Benjamin Joseph} and Rachel Riechelmann and {Del Giglio}, Auro",
year = "2011",
month = "4",
day = "1",
language = "English",
volume = "57",
pages = "211--219",
journal = "Revista da Associa{\cc}{\~a}o M{\'e}dica Brasileira (1992)",
issn = "0104-4230",
publisher = "Associacao Medica Brasileira",
number = "2",

}

TY - JOUR

T1 - Cancer-related fatigue

T2 - a review.

AU - Campos, Maira Paschoin de Oliveira

AU - Hassan, Benjamin Joseph

AU - Riechelmann, Rachel

AU - Del Giglio, Auro

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Cancer-related fatigue is the most prevalent cancer symptom, reported in 50%-90% of patients and severely impacts quality of life and functional capacity. The condition remains underreported and often goes untreated. Guidelines suggest screening for fatigue at the initial visit, when the diagnosis of advanced disease is made, and at each chemotherapy session, as well as the identification of treatable contributing factors such as anemia, hypothyroidism, depression and sleep disorders. Brief assessment tools such as the Brief Fatigue Inventory or the Visual Analog Scale may be appropriate in the initial scoring of fatigue severity, but the initial approach to treatment usually requires a more comprehensive assessment, education, and the determination of an individualized treatment plan. Patients with moderate or severe fatigue may benefit from both pharmacological and non-pharmacological interventions, whereas mild fatigue that does not interfere with quality of life can be treated with non-pharmacological measures alone. Non-pharmacological measures that have shown to be promising include cognitive-behavioral interventions such as energy conservation and activity management (ECAM), exercise and perhaps sleep therapy. Many other modalities may be beneficial and can be used on an individual basis, but there is insufficient evidence to promote any single treatment. Pharmacological therapies that have shown to be promising include the psycho-stimulants methylphenidate and dexmethylphenidate, modafinil (in severely fatigued patients only), and erythropoietin-stimulating agents in patients with chemotherapy-associated anemia and hemoglobin levels < 10 g/dL. Recently, our group reported impressive results with the use of the dry extract of Guarana (Paullinia cupana), with no significant side effects and at low cost, for the treatment of physical and mental cancer-related fatigue.

AB - Cancer-related fatigue is the most prevalent cancer symptom, reported in 50%-90% of patients and severely impacts quality of life and functional capacity. The condition remains underreported and often goes untreated. Guidelines suggest screening for fatigue at the initial visit, when the diagnosis of advanced disease is made, and at each chemotherapy session, as well as the identification of treatable contributing factors such as anemia, hypothyroidism, depression and sleep disorders. Brief assessment tools such as the Brief Fatigue Inventory or the Visual Analog Scale may be appropriate in the initial scoring of fatigue severity, but the initial approach to treatment usually requires a more comprehensive assessment, education, and the determination of an individualized treatment plan. Patients with moderate or severe fatigue may benefit from both pharmacological and non-pharmacological interventions, whereas mild fatigue that does not interfere with quality of life can be treated with non-pharmacological measures alone. Non-pharmacological measures that have shown to be promising include cognitive-behavioral interventions such as energy conservation and activity management (ECAM), exercise and perhaps sleep therapy. Many other modalities may be beneficial and can be used on an individual basis, but there is insufficient evidence to promote any single treatment. Pharmacological therapies that have shown to be promising include the psycho-stimulants methylphenidate and dexmethylphenidate, modafinil (in severely fatigued patients only), and erythropoietin-stimulating agents in patients with chemotherapy-associated anemia and hemoglobin levels < 10 g/dL. Recently, our group reported impressive results with the use of the dry extract of Guarana (Paullinia cupana), with no significant side effects and at low cost, for the treatment of physical and mental cancer-related fatigue.

UR - http://www.scopus.com/inward/record.url?scp=84856182359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856182359&partnerID=8YFLogxK

M3 - Article

C2 - 21537710

VL - 57

SP - 211

EP - 219

JO - Revista da Associação Médica Brasileira (1992)

JF - Revista da Associação Médica Brasileira (1992)

SN - 0104-4230

IS - 2

ER -